相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial
Xiao-Dong Zhang et al.
BMC GASTROENTEROLOGY (2023)
ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease
Philip O. Katz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)
Diagnosis and Treatment of Helicobacter pylori Infection
Yi-Chia Lee et al.
ANNUAL REVIEW OF MEDICINE (2022)
Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
Min Niu et al.
FRONTIERS IN PHARMACOLOGY (2022)
Implementation of WeChat-based patient-doctor interaction in the management of Helicobacter pylori infection: A propensity score matching analysis
Bo Shen Lin et al.
JOURNAL OF DIGESTIVE DISEASES (2022)
Subacromial decompression versus diagnostic arthroscopy for shoulder impingement: a 5-year follow-up of a randomised, placebo surgery controlled clinical trial
Mika Paavola et al.
BRITISH JOURNAL OF SPORTS MEDICINE (2021)
The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication ofHelicobacter pyloriinfection
Jianwei Yun et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population
Erick A. Argueta et al.
GASTROENTEROLOGY (2021)
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
Sho Suzuki et al.
GUT (2020)
The Efficacy of Berberine-Containing Quadruple Therapy on Helicobacter Pylori Eradication in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Qian Hu et al.
FRONTIERS IN PHARMACOLOGY (2020)
Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study
Siya Kong et al.
GUT PATHOGENS (2020)
Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review
Javier P. Gisbert
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
High dose PPI-amoxicillin dual therapy for the treatment ofHelicobacter pyloriinfection: a systematic review with meta-analysis
Yang-Jie Zhu et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Comparison of the effect of clarithromycin triple therapy with or withoutN-acetylcysteine in the eradication ofHelicobacter pylori: a randomized controlled trial
Chieh-Chang Chen et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes
Doron Boltin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial
Lou Yu et al.
HELICOBACTER (2019)
Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control
Hongyun Wang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
Jing Yang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
Chia-Jung Kuo et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Biotransformation of Ilaprazole in Human Liver Microsomes and Human: Role of CYP3A4 in Ilaprazole Clearance and Drug-Drug Interaction
Jie Pu et al.
DRUG METABOLISM AND DISPOSITION (2018)
Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
Wen Zhong Liu et al.
HELICOBACTER (2018)
CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
Natalia P. Denisenko et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2018)
Helicobacter pylori-induced cell death is counteracted by NF-κB-mediated transcription of DARPP-32
Shoumin Zhu et al.
GUT (2017)
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
P. Malfertheiner et al.
GUT (2017)
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection
Nazli Arslan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
William D. Chey et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression
Carmelo Scarpignato et al.
BMC MEDICINE (2016)
Multipronged regulatory functions of a novel endonuclease (TieA) from Helicobacter pylori
Savita Devi et al.
NUCLEIC ACIDS RESEARCH (2016)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
Yuuichi Sakurai et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2015)
Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori
J. C. Delchier et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment
Nicola de Bortoli et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype
M. Sugimoto et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole
Hoon Cho et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Helicobacter pylori treatment in the era of increasing antibiotic resistance
David Y. Graham et al.
GUT (2010)
Current role of acid suppressants in Helicobacter pylori eradication therapy
J Labenz
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2001)
分享论文
